Paris – March 28th, 2012 – Bryan, Garnier & Co, the independent pan-European investment bank focused on European growth companies, today announced it has advised FSI on its investment into DBV Technologies.
The Strategic Investment Fund (FSI) has invested EUR 15 million in DBV Technologies during its initial public offering on NYSE Euronext Paris. This investment allowed FSI to acquire a 12.6% stake in DBV Technologies. Bryan, Garnier & Co acted as financial advisor to FSI on this transaction.
For more information please contact:
Jean-Christophe Renondin –
Managing Director – Corporate Finance / +33 1 56 68 75 04 / email@example.com
Raquel Pires - Analyst – Corporate Finance - + 33 1 56 68 75 38 | firstname.lastname@example.org
About DBV Technologies (http://www.dbv-technologies.com/)
DBV Technologies is a French publicly owned company focused on the development of innovative products for the diagnosis and treatment of food allergies. Founded in 2002 by leading French pediatricians with funding from ANVAR, it is the only company in the world whose products are designed to epicutaneously deliver on intact skin — via an epicutaneous patch — allergens for Epicutaneous Immunotherapy (EPIT) against food allergies or for allergy diagnosis. DBV Technologies’ novel approach to food allergy diagnosis and treatment is focused on eliciting an immune response by targeting the antigen-presenting cells in the skin epidermis. The antigens (allergens) are delivered to the skin using DBV Technologies’ unique worldwide patented delivery system, VIASKIN®.
About the FSI (http://www.fonds-fsi.fr/)
Created in 2008, the FSI (Strategic Investment Fund) is a limited company in which Caisse des Dépôts has a 51% share, with the State holding 49%. FSI contributes through equity capital to French businesses whose projects create value and competitiveness for the economy. FSI acts as a minority shareholder, through involvement on its own or as a joint investor.
About Bryan, Garnier & Co (http://www.bryangarnier.com/)
Bryan, Garnier & Co is an independent investment bank specializing in European TMT, Healthcare and Renewable Energies growth companies. Bryan, Garnier & Co is positioned in three activities: Equity Research & Brokerage, Asset Management and Corporate Finance. With more than 120 professionals based in London, Paris, New York and Geneva, Bryan, Garnier & Co combines the range of services and the expertise of top-tier investment banks with the level of attention to clients of a boutique. Through its corporate finance practice, Bryan, Garnier & Co has became a leader in advising European growth companies on strategic finance transactions such as mergers & acquisitions, equity capital market, LBOs and private placement over the last three years. Bryan, Garnier & Co is authorized and regulated by the Financial Services Authority (FSA) in the United Kingdom, and is member of London Stock Exchange and Euronext, Alternext Listing Sponsor, and is active on all European capital markets.